Who makes Airipiprazole?

Airipiprazole is developed by National Institute on Drug Abuse (NIDA).

Last reviewed 2026-04-19 · How we verify

Airipiprazole

National Institute on Drug Abuse (NIDA) · Phase 1 active Small molecule

At a glance

Generic name	Airipiprazole
Sponsor	National Institute on Drug Abuse (NIDA)
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Airipiprazole CI brief — competitive landscape report
Airipiprazole updates RSS · CI watch RSS
National Institute on Drug Abuse (NIDA) portfolio CI